Taxotere is currently made by sanofi-aventis.
Taxotere is part of a group of medications called taxanes. Taxanes stop cancer cells from growing and multiplying by interfering with certain structures in the cell.
While Taxotere can kill both healthy and cancerous cells, it has a greater effect on cells that are multiplying rapidly. Generally, cancer cells multiply more rapidly than healthy cells and are therefore more affected by the drug.
One study looked at using Taxotere to treat advanced or metastatic breast cancer (cancer that has spread to other parts of the body) in people who had been unsuccessfully treated with other types of chemotherapy.
People were given either Taxotere or a combination of mitomycin (Mitozytrex
®) and vinblastine (Velban
®). Compared to the mitomycin/vinblastine combination, Taxotere increased the average survival time from 8.7 months to 11.4 months. It also delayed the progression of the cancer.
Taxotere was also studied for non-operable,
non-small cell lung cancer (NSCLC) that had not responded to previous chemotherapy. Compared to supportive care (which is care to improve the quality of life but not to treat the cancer), the medication extended the survival time and delayed the progression of the cancer.
Other studies have shown that Taxotere is also effective at treating prostate cancer,
stomach cancer, and head and neck cancer.